Ronald A. Peck

Phase I Study in Advanced Cancer Patients of a Diversified Prime-and-Boost Vaccination Protocol Using Recombinant Vaccinia Virus and Recombinant Nonreplicating Avipox Virus to Elicit Anti–Carcinoembryonic Antigen Immune Responses

John L. Marshall, Robert J. Hoyer, Mary Ann Toomey et al. · Journal of Clinical Oncology · 2000 · 357 citations

Medicine, Immunology, Oncology +17

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI).

Daniel P. Petrylak, Xīn Gào, Nicholas J. Vogelzang et al. · Journal of Clinical Oncology · 2020 · 165 citations

Medicine, Oncology, Pharmacology +16

Phase I and Pharmacokinetic Study of the Novel MDR1 and MRP1 Inhibitor Biricodar Administered Alone and in Combination With Doxorubicin

Ronald A. Peck, Jan Hewett, Matthew W. Harding et al. · Journal of Clinical Oncology · 2001 · 107 citations

Medicine, Oncology, Pharmacology +14

Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes

Gabriel N. Hortobágyi, Henry Gómez, Rubi K. Li et al. · Breast Cancer Research and Treatment · 2010 · 66 citations · Full text

Medicine, Oncology, Pharmacology +11

Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials

Linda T. Vahdat, Eva Thomas, Henri Roché et al. · Supportive Care in Cancer · 2012 · 42 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15